This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
-
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States, 80218
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27599
Sarah Cannon Research Institute University of Oklahoma, Oklahoma City, Oklahoma, United States, 73104
Mays Cancer Center / University of Texas, San Antonio, San Antonio, Texas, United States, 78229
NEXT Virginia, Fairfax, Virginia, United States, 22031
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Phanes Therapeutics,
2028-08